The SilenT AtRial FIBrillation (STAR-FIB) study programme - design and rationale.

Nozica, Nikolas; Lam, Anna; Goulouti, Eleni; Elchinova, Elena Georgieva; Spirito, Alessandro; Branca, Mattia; Servatius, Helge; Noti, Fabian; Seiler, Jens; Baldinger, Samuel H.; Haeberlin, Andreas; De Marchi, Stefano F.; Asatryan, Babken; Rodondi, Nicolas; Donzé, Jacques; Aujesky, Drahomir; Tanner, Hildegard; Reichlin, Tobias; Jüni, Peter and Roten, Laurent (2021). The SilenT AtRial FIBrillation (STAR-FIB) study programme - design and rationale. Swiss medical weekly, 151, w20421. EMH Schweizerischer Ärzteverlag 10.4414/smw.2021.20421

Nozica__SMW_2021.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND).

Download (1MB) | Preview


Anticoagulation of patients with screen-detected atrial fibrillation may prevent ischaemic strokes. The STAR-FIB study programme aims to determine the age- and sex-specific prevalence of silent atrial fibrillation and to develop a clinical prediction model to identify patients at risk of undiagnosed atrial fibrillation in a hospitalised patient population.


The STAR-FIB study programme includes a prospective cohort study and a case-control study of hospitalised patients aged 65–84 years, evenly distributed for both age and sex. We recruited 795 patients without atrial fibrillation for the cohort study (49.2% females; median age 74.8 years). All patients had three serial 7-day Holter ECGs to screen for silent atrial fibrillation. The primary endpoint will be any episode of atrial fibrillation or atrial flutter of ≥30 seconds duration. The age- and sex-specific prevalence of newly diagnosed atrial fibrillation will be estimated. For the case-control study, 120 patients with paroxysmal atrial fibrillation were recruited as cases (41.7% females; median age 74.6 years); controls will be randomly selected from the cohort study in a 2:1 ratio. All participants in the cohort study and all cases were prospectively evaluated including clinical, laboratory, echocardiographic and electrical parameters. A clinical prediction model for undiagnosed atrial fibrillation will be derived in the case-control study and externally validated in the cohort study.


The STAR-FIB study programme will estimate the age- and sex-specific prevalence of silent atrial fibrillation in a hospitalised patient population, and develop and validate a clinical prediction model to identify patients at risk of silent atrial fibrillation.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Cardiovascular Disorders (DHGE) > Clinic of Cardiology
04 Faculty of Medicine > Medical Education > Institute of General Practice and Primary Care (BIHAM)
04 Faculty of Medicine > Pre-clinic Human Medicine > CTU Bern
04 Faculty of Medicine > Department of General Internal Medicine (DAIM) > Clinic of General Internal Medicine > Centre of Competence for General Internal Medicine

UniBE Contributor:

Nozica, Nikolas, Lam, Anna, Goulouti, Eleni, Elchinova, Elena Georgieva, Spirito, Alessandro, Branca, Mattia, Servatius, Helge Simon (A), Noti, Fabian, Seiler, Jens, Baldinger, Samuel Hannes, Häberlin, Andreas David Heinrich, De Marchi, Stefano, Asatryan, Babken, Rodondi, Nicolas, Aujesky, Drahomir, Tanner, Hildegard, Reichlin, Tobias Roman, Roten, Laurent


600 Technology > 610 Medicine & health
300 Social sciences, sociology & anthropology > 360 Social problems & social services




EMH Schweizerischer Ärzteverlag


[4] Swiss National Science Foundation ; [116] Swiss Heart Foundation = Schweizerische Herzstiftung




Tobias Tritschler

Date Deposited:

15 Mar 2021 11:08

Last Modified:

29 Mar 2023 23:37

Publisher DOI:


PubMed ID:





Actions (login required)

Edit item Edit item
Provide Feedback